Log in to save to my catalogue

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuva...

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuva...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8979645

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

About this item

Full title

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

Publisher

New York: Springer US

Journal title

Breast cancer research and treatment, 2022-02, Vol.192 (1), p.153-161

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

Background
The NSABP B-36 compared four cycles of doxorubicin and cyclophosphamide (AC) with six cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC-100) in node-negative early-stage breast cancer. A sub-study within B-36, focusing on symptoms, quality of life (QOL), menstrual history (MH), and cardiac function (CF) was conducted.

Alternative Titles

Full title

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8979645

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8979645

Other Identifiers

ISSN

0167-6806

E-ISSN

1573-7217

DOI

10.1007/s10549-021-06475-2

How to access this item